Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker

被引:3
作者
Dimas, C
Frangos-Plemenos, M
Kouskouni, E
Kondis-Pafitis, A
机构
[1] Areteion Hosp, Athens Med Sch, Dept Microbiol, Athens 11528, Greece
[2] Areteion Hosp, Athens Med Sch, Dept Pathol, Athens 11528, Greece
关键词
breast cancer; DF3; HER2; immunohistochemistry; p185; tumor marker;
D O I
10.1046/j.1525-1438.2002.01073.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human epidermal growth factor receptor 2 (p185 HER2) oncoprotein immunohistochemical expression and DF3 antigen distribution were evaluated in 129 patients with primary breast cancer. p185 HER2 overexpession was positively correlated with the degree of differentiation, metastatic disease, progesterone receptors, and cytoplasmic distribution of DF3 antigen. p185 HER2 overexpression had prognostic significance for the disease-free interval.
引用
收藏
页码:74 / 79
页数:6
相关论文
共 38 条
[1]  
BANDYOPADHYAY D, 1992, ONCOLOGY, V49, P9
[2]   PROGNOSTIC ASSOCIATION OF C-ERBB-2 ONCOGENE AMPLIFICATION AND PROTEIN OVEREXPRESSION IN HUMAN BREAST-CANCER USING ARCHIVAL TISSUES - A COMPARATIVE-STUDY [J].
BANDYOPADHYAY, D ;
REDKAR, A ;
BHARDE, S ;
DANI, H ;
SAMPAT, M ;
MITTRA, I .
ACTA ONCOLOGICA, 1994, 33 (05) :493-498
[3]   PREVALENCE OF AMPLIFICATION OF THE ONCOGENES C-MYC, HER2 NEU, AND INT-2 IN 1000 HUMAN BREAST-TUMORS - CORRELATION WITH STEROID-RECEPTORS [J].
BERNS, EMJJ ;
KLIJN, JGM ;
VANSTAVEREN, IL ;
PORTENGEN, H ;
NOORDEGRAAF, E ;
FOEKENS, JA .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :697-700
[4]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[5]   CIRCULATING CA 15-3 LEVELS IN THE POSTSURGICAL FOLLOW-UP OF BREAST-CANCER PATIENTS AND IN NON-MALIGNANT DISEASES [J].
COLOMER, R ;
RUIBAL, A ;
GENOLLA, J ;
RUBIO, D ;
DELCAMPO, JM ;
BODI, R ;
SALVADOR, L .
BREAST CANCER RESEARCH AND TREATMENT, 1989, 13 (02) :123-133
[6]  
DELVENNE CG, 1992, EUR J CANCER, V28A, P700
[7]   Assessment of HER2 status in breast cancer: why, when and how? [J].
Dowsett, M ;
Cooke, T ;
Ellis, I ;
Gullick, WJ ;
Gusterson, B ;
Mallon, E ;
Walker, R .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (02) :170-176
[8]   Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micrometastases from breast cancer patients [J].
Gebhardt, F ;
Zänker, KS ;
Brandt, B .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (02) :319-323
[9]  
Giovagnoli M. R., 1994, International Journal of Biological Markers, V9, P140
[10]  
HARTMAN LC, 1994, CANCER, V74, P1956